{
    "clinical_study": {
        "@rank": "55556", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      Assess whether 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) at 0.6 mg/kg\n      per day prevents liver failure in at least 1 patient with tyrosinemia type I."
        }, 
        "brief_title": "Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I", 
        "condition": "Tyrosinemia, Type I", 
        "condition_browse": {
            "mesh_term": "Tyrosinemias"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Only 2 patients with tyrosinemia type I are known to this research team;\n      others will be treated if found and if clinical conditions permit.\n\n      The enzyme inhibitor 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) is\n      administered orally, in 2 divided doses daily with meals.\n\n      Patients will be followed closely for side effects attributable to NTBC."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        Tyrosinemia type I No cirrhosis No hepatocellular carcinoma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004333", 
            "org_study_id": "199/11892", 
            "secondary_id": "UMMC-1319"
        }, 
        "intervention": {
            "intervention_name": "NTBC", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Enzyme Inhibitors"
        }, 
        "keyword": [
            "inborn errors of metabolism", 
            "rare disease", 
            "tyrosinemia I"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "University of Michigan", 
            "last_name": "Jess G. Thoene", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004333"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "University of Michigan", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "November 1994", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2000"
    }, 
    "geocoordinates": {}
}